Jason Butler
Stock Analyst at JMP Securities
(2.19)
# 2,673
Out of 4,847 analysts
141
Total ratings
35.25%
Success rate
-2.62%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRTA Prothena Corporation | Maintains: Market Outperform | $78 → $29 | $4.83 | +500.41% | 10 | May 27, 2025 | |
| VIGL Vigil Neuroscience | Downgrades: Market Perform | n/a | $7.91 | - | 5 | May 22, 2025 | |
| TTD The Trade Desk | Maintains: Market Outperform | $115 → $100 | $74.40 | +34.41% | 1 | May 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Market Outperform | $42 → $38 | $14.45 | +162.98% | 8 | May 7, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Market Outperform | $33 | $7.74 | +326.36% | 3 | Apr 30, 2025 | |
| CYTK Cytokinetics | Reiterates: Market Outperform | $78 | $32.00 | +143.75% | 16 | Apr 10, 2025 | |
| RAPP Rapport Therapeutics | Initiates: Market Outperform | $28 | $12.24 | +128.76% | 1 | Apr 8, 2025 | |
| PGEN Precigen | Reiterates: Market Outperform | $6 | $1.36 | +341.18% | 9 | Mar 20, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Market Outperform | $17 → $18 | $8.87 | +102.93% | 2 | Mar 12, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $4 | $1.05 | +280.95% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $580.10 | +20.84% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $33 | $10.01 | +229.67% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $4.42 | +103.62% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $72 → $73 | $53.31 | +36.93% | 13 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $3.18 | +183.02% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $39 | $12.08 | +222.85% | 4 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.30 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $50 → $23 | $1.58 | +1,355.70% | 3 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $12.61 | +50.67% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $39 | $21.98 | +77.43% | 13 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $0.61 | +3,507.15% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.76 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $8.97 | +468,127.42% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $7.19 | +1,513.35% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $3.45 | +160.87% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.30 | - | 1 | Dec 2, 2020 |
Prothena Corporation
May 27, 2025
Maintains: Market Outperform
Price Target: $78 → $29
Current: $4.83
Upside: +500.41%
Vigil Neuroscience
May 22, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $7.91
Upside: -
The Trade Desk
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $74.40
Upside: +34.41%
Viridian Therapeutics
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $14.45
Upside: +162.98%
ABIVAX Société Anonyme
Apr 30, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $7.74
Upside: +326.36%
Cytokinetics
Apr 10, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $32.00
Upside: +143.75%
Rapport Therapeutics
Apr 8, 2025
Initiates: Market Outperform
Price Target: $28
Current: $12.24
Upside: +128.76%
Precigen
Mar 20, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $1.36
Upside: +341.18%
Zevra Therapeutics
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $8.87
Upside: +102.93%
Esperion Therapeutics
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $1.05
Upside: +280.95%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $580.10
Upside: +20.84%
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $10.01
Upside: +229.67%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $4.42
Upside: +103.62%
Nov 1, 2024
Maintains: Market Outperform
Price Target: $72 → $73
Current: $53.31
Upside: +36.93%
Oct 8, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $3.18
Upside: +183.02%
Sep 4, 2024
Reiterates: Market Outperform
Price Target: $39
Current: $12.08
Upside: +222.85%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.30
Upside: -
Jul 26, 2024
Maintains: Market Outperform
Price Target: $50 → $23
Current: $1.58
Upside: +1,355.70%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $12.61
Upside: +50.67%
Mar 12, 2024
Maintains: Outperform
Price Target: $44 → $39
Current: $21.98
Upside: +77.43%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $0.61
Upside: +3,507.15%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.76
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $8.97
Upside: +468,127.42%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $7.19
Upside: +1,513.35%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $3.45
Upside: +160.87%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $0.30
Upside: -